Breaking News

Radiant Biotherapeutics Unveils $8M Financing and Two Partnerships

Multabody platform demonstrates the potential to deliver a new class of multi-functional biologics to tackle complex and diverse diseases.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Radiant Biotherapeutics, an antibody platform company developing multi-valent, multi-specific therapeutics, has unveiled an $8 million seed financing and two pharmaceutical partnerships. Radiant is based on foundational IP from the labs of Dr. Jean-Philippe Julien at The Hospital for Sick Children (SickKids) and Dr. Bebhinn Treanor at the University of Toronto. It was created by Amplitude Ventures which also led the seed round along with launch partner, SickKids and investors Alexandria Investme...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters